A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

October 15, 2025

Study Completion Date

December 30, 2025

Conditions
Ovarian CancerClear Cell CarcinomaEndometrial CancerCervical CarcinomaMetastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
BIOLOGICAL

vudalimab

Monoclonal bispecific antibody

Trial Locations (17)

10016

NYU Langone Health, New York

10032

Columbia University Medical Center, New York

19104

University of Pennsylvania Health System, Philadelphia

19713

Medical Oncology Hematology Consultants, PA, Newark

23502

Virginia Oncology Associates, Norfolk

30322

Winship Cancer Institute, Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

48201

Karmanos Cancer Institute, Detroit

78745

Texas Oncology - Central South, Austin

80012

Rocky Mountain Cancer Centers, Aurora

86301

Arizona Oncology Associates, PC - NAHOA, Prescott

89148

Comprehensive Cancer Centers of Nevada-Southern Hills, Las Vegas

90067

Valkyrie Clinical Trials, Los Angeles

92004

UCLA Medical Center, Los Angeles

92037

UCSD Moores Cancer Center, La Jolla

92505

Kaiser Permanente Medical Group, Riverside

94158

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Xencor, Inc.

INDUSTRY